These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37170275)

  • 1. Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma.
    Erlmeier M; Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
    BMC Urol; 2023 May; 23(1):90. PubMed ID: 37170275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of claudin-6 in chromophobe renal cell carcinoma.
    Erlmeier F; Zschäbitz S; Mikuteit M; Autenrieth M; Weichert W; Hartmann A; Steffens S
    Histol Histopathol; 2023 Apr; 38(4):403-407. PubMed ID: 36128931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trophoblast Cell Surface Antigen 2 (Trop2) in Chromophobe Renal Cell Carcinoma.
    Mikuteit M; Steffens S; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Erlmeier F
    Oncology; 2022; 100(6):331-336. PubMed ID: 35168242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma.
    Mikuteit M; Zschäbitz S; Erlmeier M; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
    Oncology; 2022; 100(10):536-541. PubMed ID: 35760058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations.
    Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
    Oncology; 2024; 102(6):503-509. PubMed ID: 38043528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
    Erlmeier F; Hartmann A; Autenrieth M; Wiedemann M; Ivanyi P; Steffens S; Weichert W
    Med Oncol; 2016 Nov; 33(11):120. PubMed ID: 27696122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
    Erlmeier F; Weichert W; Autenrieth M; Wiedemann M; Schrader AJ; Hartmann A; Ivanyi P; Steffens S
    Med Oncol; 2017 May; 34(5):71. PubMed ID: 28353093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.
    Casuscelli J; Becerra MF; Seier K; Manley BJ; Benfante N; Redzematovic A; Stief CG; Hsieh JJ; Tickoo SK; Reuter VE; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Clin Genitourin Cancer; 2019 Oct; 17(5):373-379.e4. PubMed ID: 31326335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma.
    Zhao W; Tian B; Wu C; Peng Y; Wang H; Gu WL; Gao FH
    Pathol Res Pract; 2015 Apr; 211(4):303-7. PubMed ID: 25596994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
    Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
    Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HNF-1β as an immunohistochemical marker for distinguishing chromophobe renal cell carcinoma and hybrid oncocytic tumors from renal oncocytoma.
    An J; Park CK; Kim M; Joo JW; Cho NH
    Virchows Arch; 2021 Mar; 478(3):459-470. PubMed ID: 32816058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
    Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
    Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Met in chromophobe renal cell carcinoma.
    Erlmeier F; Ivanyi P; Hartmann A; Autenrieth M; Wiedemann M; Weichert W; Steffens S
    Med Oncol; 2017 Feb; 34(2):15. PubMed ID: 28035577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical study of c-KIT (CD117) expression in renal cell carcinoma.
    Ahmed EA; Youssif ME
    J Egypt Natl Canc Inst; 2009 Jun; 21(2):121-32. PubMed ID: 21057563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor.
    Tanimoto S; Fukumori T; El-Moula G; Shiirevnyamba A; Kinouchi S; Koizumi T; Nakanishi R; Yamamoto Y; Taue R; Yamaguchi K; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Takahashi M; Kanayama HO
    J Med Invest; 2008 Feb; 55(1-2):106-11. PubMed ID: 18319552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched Analysis.
    Frees S; Kamal MM; Knoechlein L; Bell R; Ziesel C; Neisius A; Thomas C; Brenner W; Jäger W; Thüroff JW; Roos FC
    Urology; 2016 Dec; 98():81-87. PubMed ID: 27262395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms.
    Petit A; Castillo M; Santos M; Mellado B; Alcover JB; Mallofré C
    Am J Surg Pathol; 2004 May; 28(5):676-8. PubMed ID: 15105658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
    Yu W; Wang Y; Jiang Y; Zhang W; Li Y
    BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.